These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32659476)

  • 1. Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc).
    Jiang Y; Turk MA; Pope JE
    Autoimmun Rev; 2020 Sep; 19(9):102602. PubMed ID: 32659476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
    Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
    J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary arterial hypertension and systemic sclerosis relation: a single centre experience.
    Demir N; Şahin A; Küçükşahin O; Kayacan O; Dinçer İ; Sayın T; Karnak D; Turgay M
    Heart Lung Circ; 2014 Jul; 23(7):667-73. PubMed ID: 24613044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
    Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
    Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
    Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
    Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis.
    Theodorakopoulou MP; Minopoulou I; Sarafidis P; Kamperidis V; Papadopoulos C; Dimitroulas T; Boutou AK
    Rheumatol Int; 2021 Jun; 41(6):1045-1053. PubMed ID: 33830321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
    Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
    Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes.
    Brown Z; Proudman S; Morrisroe K; Stevens W; Hansen D; Nikpour M
    Semin Arthritis Rheum; 2021 Jun; 51(3):495-512. PubMed ID: 33857705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
    Mullin CJ; Khair RM; Damico RL; Kolb TM; Hummers LK; Hassoun PM; Steen VD; Mathai SC;
    Arthritis Rheumatol; 2019 Oct; 71(10):1691-1700. PubMed ID: 31066998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis.
    Didriksen H; Molberg Ø; Fretheim H; Gude E; Jordan S; Brunborg C; Palchevskiy V; Garen T; Midtvedt Ø; Andreassen AK; Distler O; Belperio J; Hoffmann-Vold AM
    Arthritis Rheumatol; 2021 Jul; 73(7):1277-1287. PubMed ID: 33497027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity.
    Takagi K; Kawamoto M; Higuchi T; Tochimoto A; Harigai M; Kawaguchi Y
    Int J Rheum Dis; 2020 May; 23(5):674-680. PubMed ID: 32144871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review.
    Gladue H; Altorok N; Townsend W; McLaughlin V; Khanna D
    Semin Arthritis Rheum; 2014 Feb; 43(4):536-41. PubMed ID: 24012044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.
    Proudman SM; Stevens WM; Sahhar J; Celermajer D
    Intern Med J; 2007 Jul; 37(7):485-94. PubMed ID: 17547726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study.
    Thakkar V; Stevens W; Prior D; Rabusa C; Sahhar J; Walker JG; Roddy J; Lester S; Rischmueller M; Zochling J; Nash P; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):129-136. PubMed ID: 27214686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?
    Senturk B; Akdeniz B; Yilmaz MB; Ozcan Kahraman B; Acar B; Uslu S; Birlik M
    Clin Rheumatol; 2020 Jan; 39(1):49-56. PubMed ID: 31129792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort.
    Bauer Y; de Bernard S; Hickey P; Ballard K; Cruz J; Cornelisse P; Chadha-Boreham H; Distler O; Rosenberg D; Doelberg M; Roux S; Nayler O; Lawrie A
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.